Notice for trametinib (Novartis Pharmaceuticals Australia Pty Ltd)
Active ingredients
trametinib
Date of review outcome
Lapse date
Type
Priority review
Indication
Trametinib, in combination with dabrafenib, is indicated for the adjuvant treatment of patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.
Registration date